Grace Therapeutics (GRCE) AI Stock Analysis

1,210 Followers

Grace Therapeutics

(NASDAQ:GRCE)

Select Model

Rating:49Neutral

Price Target:$2.00▲(7.82% Upside)

Action:reiterated

Date:09/19/26

The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn) and a weak technical trend (trading below key moving averages with soft momentum). Offsetting this, recent financing that management expects to extend runway to end of 2028 provides near-term balance-sheet support, while valuation signals remain constrained by negative earnings and no dividend.

Positive Factors

Low Financial LeverageAn effectively debt-free balance sheet limits interest expense and reduces refinancing pressure while the company advances its pipeline. This gives management greater flexibility to direct available capital toward development and regulatory work, although it does not eliminate the need for future funding.

Negative Factors

No Commercial RevenueZero revenue indicates that GRCE remains pre-commercial and has not yet established an operating stream to support research, regulatory or corporate expenses. Until a product generates sales, the company’s financial outlook remains dependent on pipeline progress and access to external capital.

Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $30.19M
Dividend Yield: ―
Average Volume (3M): 126.37K
Price to Earnings (P/E): -1.5
Beta (1Y): 1.23
Revenue Growth: ―
EPS Growth: -43.60%
Country: US
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Grace Therapeutics Business Overview & Revenue Model

Company Description

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-...

Grace Therapeutics Financial Statement Overview

Summary

Pre-commercial profile with zero revenue and persistent losses (TTM net loss ~$21.5M) plus ongoing negative free cash flow (TTM FCF about -$10.3M). The main offset is a low-debt balance sheet, but equity has been declining, keeping financing dependence as a key risk.

Income Statement

18Very Negative

Balance Sheet

66Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-2,000	0	0	0	0	0
EBITDA	-25.68M	-11.07M	-23.75M	-15.41M	-24.56M	-19.17M
Net Income	-21.45M	-7.79M	-13.63M	-17.44M	-57.39M	-12.27M
Balance Sheet
Total Assets	50.07M	66.65M	71.99M	73.30M	79.12M	128.62M
Cash, Cash Equivalents and Short-Term Investments	13.76M	16.98M	22.13M	23.00M	27.89M	43.66M
Total Debt	0	0	0	0	485.00K	295.00K
Total Liabilities	1.86M	2.76M	5.38M	11.56M	11.17M	20.35M
Stockholders Equity	48.21M	63.90M	66.61M	61.74M	67.95M	108.27M
Cash Flow
Free Cash Flow	-10.30M	-8.87M	-14.90M	-12.36M	-15.93M	-17.23M
Operating Cash Flow	-10.30M	-8.87M	-14.90M	-12.33M	-15.91M	-17.23M
Investing Cash Flow	0	0	0	104.00K	13.15M	-3.52M
Financing Cash Flow	4.04M	3.71M	14.03M	7.36M	304.00K	0

Grace Therapeutics Technical Analysis

Technical Analysis SentimentNegative

Last Price1.85

Price Trends

50DMA2.02Negative

100DMA2.14Negative

200DMA2.74Negative

Market Momentum

MACD-0.05Negative

RSI44.45Neutral

STOCH47.94Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Negative. The current price of 1.85 is below the 20-day moving average (MA) of 1.89, below the 50-day MA of 2.02, and below the 200-day MA of 2.74, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.45 is Neutral, neither overbought nor oversold. The STOCH value of 47.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRCE.

Grace Therapeutics Risk Analysis

Grace Therapeutics disclosed 53 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.We face risks related to the growth of artificial intelligence and data analytics.Q1, 2026

2.We received a Complete Response Letter (CRL) from the FDA citing certain manufacturing deficiencies and other non-clinical issues, which may delay or prevent approval of GTx-104.Q1, 2026

3.If our current CMO is unable to timely resolve the deficiencies identified by the FDA in the CRL related to GTx-104, we may be required to engage an alternative manufacturer, which could result in significant delays, increased costs, or our inability to obtain regulatory approval or commercialize GTx-104 at all.Q1, 2026

Grace Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GRCE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56Neutral	$128.17M	-4.46	-311.07%	―	―	54.60%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GRCE	49Neutral	$39.13M	-1.48	-35.78%	―	―	-43.60%
CVKD	47Neutral	$5.14M	-0.29	-406.38%	―	―	44.80%
INKT	41Neutral	$51.08M	-4.28	83.45%	―	―	15.65%
ALGS	40Underperform	$18.11M	-0.34	-206.30%	―	1171.58%	49.20%

* Healthcare Sector Average

Performance Comparison

GRCE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GRCE	Grace Therapeutics, Inc.	1.85	-1.25	-40.16%
PYPD	PolyPid Ltd.	6.60	3.02	84.36%
ALGS	Aligos Therapeutics, Inc.	2.16	-3.91	-64.42%
INKT	Mink Therapeutics, Inc.	10.22	-3.00	-22.67%
CVKD	Cadrenal Therapeutics, Inc.	1.45	-10.20	-87.55%

Grace Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings

Grace Therapeutics Shareholders Back Board, Pay and Auditor

Positive

Sep 18, 2026

Grace Therapeutics, Inc. held its Annual Meeting of Stockholders on September 17, 2026, with 61.28% of outstanding common shares represented, reflecting a solid level of investor participation in the company’s governance. Stockholders elected five di...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026

Grace Therapeutics AI Stock Analysis